Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Down 4% in 2025

MT Newswires

Mar 31

Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) profit attributable to owners fell by 4% in 2025 to 2.13 billion yuan from 2.23 billion yuan a year earlier, according to a Monday filing with the Singapore Exchange.

Shares of the pharmaceutical company were down under 1% in Tuesday trading.

Earnings per share stood at 2.77 yuan compared with 2.90 yuan in the year-ago period.

Revenue declined 33% year over year to 4.92 billion yuan from 7.31 billion yuan, mainly due to a change in the company's consolidation scope.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2623988374"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2623988374\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2623988374?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 11:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623988374","market":"sg","top_or_hot":-1,"title":"Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Down 4% in 2025","media":"MT Newswires","content":"<html><body><p> Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) profit attributable to owners fell by 4% in 2025 to 2.13 billion yuan from 2.23 billion yuan a year earlier, according to a Monday filing with the <a href=\"https://laohu8.com/S/S68.SI\">Singapore Exchange</a>.</p><p>Shares of the pharmaceutical company were down under 1% in Tuesday trading.</p><p>Earnings per share stood at 2.77 yuan compared with 2.90 yuan in the year-ago period.</p><p>Revenue declined 33% year over year to 4.92 billion yuan from 7.31 billion yuan, mainly due to a change in the company's consolidation scope.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Pharmaceutical Da Ren Tang's Attributable Profit Down 4% in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Pharmaceutical Da Ren Tang's Attributable Profit Down 4% in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060499803\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires </p>\n<p class=\"h-time\">2026-03-31 11:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) profit attributable to owners fell by 4% in 2025 to 2.13 billion yuan from 2.23 billion yuan a year earlier, according to a Monday filing with the <a href=\"https://laohu8.com/S/S68.SI\">Singapore Exchange</a>.</p><p>Shares of the pharmaceutical company were down under 1% in Tuesday trading.</p><p>Earnings per share stood at 2.77 yuan compared with 2.90 yuan in the year-ago period.</p><p>Revenue declined 33% year over year to 4.92 billion yuan from 7.31 billion yuan, mainly due to a change in the company's consolidation scope.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"T14.SI","symbol_name":"达仁堂","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2623988374","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623988374","pubTimestamp":1774928424,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tianjin Pharmaceutical Da Ren Tang's  profit attributable to owners fell by 4% in 2025 to 2.13 billion yuan from 2.23 billion yuan a year earlier, according to a Monday filing with the Singapore Exchange.Shares of the pharmaceutical company were down under 1% in Tuesday trading.Earnings per share stood at 2.77 yuan compared with 2.90 yuan in the year-ago period.Revenue declined 33% year over year to 4.92 billion yuan from 7.31 billion yuan, mainly due to a change in the company's consolidation scope.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"T14.SI":"达仁堂","BK6506":"制药与医学研究概念","BK6079":"制药"},"translate_title":"天津医药达人堂2025年归属利润下降4%","themeId":"b010cf239ffd4765bcd3edd8f767f746","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"T14.SI":0.9},"content_text":"Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) profit attributable to owners fell by 4% in 2025 to 2.13 billion yuan from 2.23 billion yuan a year earlier, according to a Monday filing with the Singapore Exchange.Shares of the pharmaceutical company were down under 1% in Tuesday trading.Earnings per share stood at 2.77 yuan compared with 2.90 yuan in the year-ago period.Revenue declined 33% year over year to 4.92 billion yuan from 7.31 billion yuan, mainly due to a change in the company's consolidation scope.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}